Purpose: Circulating endothelial cells (CEC) have been widely used as a prognostic biomarker and regarded as a promising strategy for monitoring the response to treatment in several cancers. However, the presence and biologic roles of CECs have remained controversial for decades because technical standards for the identification and quantification of CECs have not been established. Here, we hypothesized that CECs detected by flow cytometry might be monocytes rather than endothelial cells.
Introduction
Overcoming resistance to therapy is the ultimate goal of the development of novel treatment modalities in cancer (1) . The biologic heterogeneity and genetic instability of cancer cells are significant barriers for the design of effective therapies. Therefore, relatively more homogenous and genetically stable host factors have been suggested as alternative targets (2) . Angiogenesis, which is one of the common and crucial steps in the development and progression of solid tumors, is a host-dependent process and, consequently, has been introduced as an attractive target of cancer treatment (3) . A significant number of drugs designed to interrupt the establishment of tumor-associated vasculature by neutralizing vasculogenic factors is currently in clinical trials and some of them have been approved for clinical use in patients with cancer (4, 5) . However, understanding the mechanisms of angiogenesis and establishing validated markers that accurately reflect the pharmacologic effects of antiangiogenic therapeutics remain major challenges (6) .
Because circulating endothelial cells (CEC) are likely to contribute to new vessel formation (7) and their levels in the blood change in response to pro-or antiangiogenic drugs (8) (9) (10) , the measurement of CECs (total CECs including progenitor cells) has been regarded as a promising strategy for monitoring tumor angiogenesis. Several studies reported a significant increase in the number of CECs in patients with cancer with progressive disease (i.e., lymphoma, breast cancer, renal cancer, etc.; refs. [11] [12] [13] . In addition, studies have shown that CEC kinetics and viability correlate well with clinical outcomes of patients with cancer undergoing antiangiogenic treatment (14, 15) .
However, the presence and role of CECs have been controversial for decades because trials using CECs as a diagnostic parameter or a therapeutic target did not produce consistent results. Moreover, markers that accurately identify CECs have not been established because many circulating cells such as monocytes express many of the same markers as endothelial cells (16) . Consequently, the detection and estimation of CECs have remained challenging as they comprise a small proportion of peripheral blood cells, and there is no consensus in the immunophenotype of CEC (17) . The application of various combinations of markers or different enumeration techniques to the detection of CECs has produced discrepant results in the amount and immunophenotype of CECs (18) (19) (20) . Furthermore, certain authors have questioned whether CECs detected by flow cytometry are authentic endothelial cells and their function in angiogenesis, if any (17, 21) . Recent studies have suggested that the actual angiogenic cell types incorporated into newly formed vessels are myeloid cells such as monocytes (22) (23) (24) rather than CECs and/or their progenitor cells. Therefore, establishing a method to validate the identity of CECs detected by flow cytometry and to assess their biologic significance is critical before expanding their clinical use.
Considering the angiogenic role of monocytes and the technical hurdles of flow cytometry, we hypothesized that a subset of circulating cells detected by flow cytometry using conventional CEC markers might be monocytes rather than endothelial cells. To show this, we first evaluated the flow-cytometric techniques and markers currently in use and analyzed the frequency of representative CEC subsets (i.e., CD45 Table S1 ). All healthy volunteers were free of any medications and had no cardiovascular disease. The Institutional Review Board at Kwandong University College of Medicine (Seoul, Republic of Korea) approved all protocols, and informed consent was obtained from all subjects.
Antibodies for flow cytometry
The following monoclonal antibodies directly conjugated with fluorescein isothiocyanate (FITC), phycoerythrin (PE), peridinin chlorophyll A protein (PerCP), or allophycocyanin (APC) were used for flow-cytometric analysis: anti-CD31 FITC (WM-59 clone), anti-CD61 FITC (VI-PL2 clone), anti-CD3 PE (SK7 clone), anti-CD19 PE (HIB19 clone), anti-CD31 PE (WM-59 clone), anti-CD41a PE (HIP8 clone), anti-CD56 PE (MY31 clone), anti-CD146 PE (P1H12 clone), anti-CD45 PerCP (2D1 clone), and anti-CD14 APC (M5E2 clone). Isotype-matched FITC-, PE-, PerCP-, and APC-conjugated control antibodies were purchased from BD Biosciences. Anti-CD105 PE (SN6 clone) and isotype-matched PE-conjugated control antibodies were purchased from Serotec. Anti-CD31 APC (WM-59 clone) and isotype-matched APC-conjugated control antibodies were purchased from eBioscience.
Preparation of peripheral blood mononuclear cells
Peripheral blood was collected from healthy volunteers and patients with cancer using EDTA as an anticoagulant and processed within several hours after collection as follows: whole blood was diluted 1:1 (vol/vol) with PBS containing 0.5% bovine serum albumin (BSA) and 2 mmol/L EDTA and overlaid onto an equal volume of Ficoll
Translational Relevance
Circulating endothelial cells (CEC) are recognized as a marker of tumor angiogenesis and a predictor of prognosis, as well as a target for therapy. However, their presence in the peripheral blood of patients with cancer and role in angiogenesis remain controversial. Our results showed that CD45 
Immunofluorescence staining
Immunocytochemical fluorescence labeling of cells was conducted as previously described (24) . Briefly, CD45
À / CD31 þ cells isolated by flow cytometry were cytospun onto glass slides and washed 3 times with PBS for 3 minutes. To stain intracellular antigens, cells were permeabilized with 0.5% Triton X-100 (Sigma Chemical Co.). To prevent crossreaction with antibodies used to stain cells in the flowcytometric analysis, Fab-fragment blocking was conducted overnight at 4 C with an antibody from the same host species of antibody, which was a F(ab 0 )2 fragment from goat anti-mouse immunoglobulin G (IgG) (Jackson ImmunoResearch Laboratories) in this study. After the blocking step, cells were stained with the following antibodies: mouse anti-human CD105 monoclonal antibody (mAb; 1:100, Serotec), mouse anti-human CD146 mAb (1:100 dilution, Chemicon), mouse anti-human CD144 mAb (1:100, Reliatech GmbH), mouse anti-human CD68 mAb (1:100 dilution, DAKO), polyclonal rabbit anti-human vWF Ab (1:100 dilution, DAKO), or mouse anti-human CD14 mAb (1:20 dilution, DAKO), followed by labeling with the corresponding secondary antibodies conjugated with FITC or Texas Red. For double-staining experiments, Table 1 . Antibody panels used for flow-cytometric analysis and isolation of CD45 the protein and fragment blocking steps were repeated before treating with the second primary antibody to prevent cross-reaction. Cell nuclei were counterstained with Hoechst 33342 dye (Invitrogen). The slides were then washed 3 times with PBS for 3 minutes each and mounted in Vecta-shield (Vector Laboratories). Images were acquired with a LSM510 Meta DuoScan confocal system (Zeiss).
Statistical analysis
The Mann-Whitney U test was used to determine the statistical significance of differences in the frequencies of CEC candidates between the peripheral blood collected from patients with cancer and healthy volunteers. All statistical tests were two-sided. P values less than 0.05 were considered significant.
Results

Establishment of flow cytometry gating strategies for the measurement of circulating endothelial cells
First, we found that monocytes showed higher levels of autofluorescence than lymphocytes (data not shown), indicating that they should be analyzed separately for fluorescence compensation. In flow-cytometric analysis, the detection of equal levels of autofluorescence in positive and negative populations for each single stain indicates that the fluorescent compensation is appropriate (29) . As an initial step to establish the efficient gating strategies for the detection of CECs by flow cytometry, we attempted to determine the subset(s) of PBMCs expressing the CD45 À /CD31 (Fig. 1B) nor FSC mid / SSC high fractions (data not shown). In the polychromatic flow-cytometric analysis used in the present study, adequate threshold was assessed by fluorescence-minus-one (FMO) gating, which consists of analyzing cells stained with all antibodies except the one being tested (30) . To investigate the effects of the gating controls on the actual event frequencies, the flow-cytometric analysis of the singlet lymphocyte fraction was conducted using either the isotype control or the FMO control ( Fig. 2A) . Because the negative threshold of the FMO control ( Fig. 2A,  b ) was higher than that of the isotype control ( Fig. 2A, a) , gating with FMO controls could decrease the false-positive event frequencies. In line with the study by Cui and colleagues (31), gating with FMO controls was shown to be a more efficient method to increase the accuracy and specificity of the positive signals in polychromatic flow-cytometric detection of rare events, such as CECs, than the use of isotype controls.
On the basis of these results, we established a gating strategy to determine the frequencies of CECs in PBMCs, as described in Fig. 2B . In brief, cells were stained with a panel of antibodies in parallel with FMO controls. The singlet lymphocyte population was identified on a FSC/ SSC plot and subgated onto a bivariant antigen plot to identify CD45
þ cells. These cells were further subgated to identify the corresponding CD146 þ or CD105 þ subpopulation.
Flow-cytometric analysis of CECs in PBMCs
A number of protein markers including CD31, CD34, CD105, CD146, CD144, and VEGF receptor-2 have been used to define CECs. However, there is no truly specific marker to identify CECs because those markers are also expressed in other type of cells (32) . A generally accepted definition of CECs is CD45
À /CD31 þ cells expressing CD146 or CD105 (11) , but this definition needs to be modified. According to the gating strategy described above, we examined the frequencies of CD45
PBMCs of patients with cancer (n ¼ 56) and healthy volunteers (n ¼ 44) by flow cytometry. The frequency of CD45 À /CD31 þ cells was significantly higher in the singlet FSC low /SSC low population of patients with cancer (median, 1.365%; range, 0.110-26.85%) than in that of healthy volunteers (median, 0.183%; range, 0.027-3.980%; P < 0.0001) as shown in Fig. 3A . In contrast with a previous report (11) , the frequency of CD45
in healthy volunteers (median, 0%; range, 0-0.003%) and patients with cancer (median, 0.001%; range, 0-0.016%) was lower than the cutoff values of the FMO control group (median, 0.007%; range, 0-0.021%), indicating that estimation of the frequency of those cells is not possible both in cancer patients and healthy controls due to the limited resolution of the flow cytometry. Actually, when the isotype control was used, the frequencies of
þ cells were significantly higher (median, 0.041%; range, 0.007-0.132%; Fig. 2C ), underscoring the importance of using FMO controls. Meanwhile, CD146 expression was detected only in the CD45 þ /CD31 À subpopulation of the FSC low /SSC low populations (Fig. 1A) . These CD146-positive cells also expressed CD3 (data not shown). These results, together with those of previous studies showing that CD146 is present in a subset of activated T lymphocytes (21, 33) , indicate that CD146 There was no significant statistical difference in the frequency of CD45 Fig. 4A and B, respectively) . Furthermore, anucleated CD45 À /CD31 þ cells stained negative for anti-CD146, anti-CD105, and anti-CD144 antibodies but positive for vWF, a common marker of endothelial cells and platelets (Fig. 5B, top) as assessed by immunocytochemical staining and confocal microscopy. These results together with the morphologic phenotypes of 
/CD31
þ cells were (Fig. 5B, bottom) but negative for vWF (Fig. 5B, top) . Furthermore, these cells expressed the monocyte-specific antigen CD14 (Fig. 5C ). CD45 þ / CD31 À cells (mostly lymphocytes) were used as a negative control for CD68, vWF, and CD14 expression, whereas CD45 þ /CD31 þ cells (mostly monocytes) were used as a positive control for CD68 and CD14 expression ( Fig. S1 ). Collectively, these data indicate that anucleated CD45 À / CD31 þ cells were mainly platelets, and CD45 À /CD31 þ / CD105 þ cells were derived from monocytes/macrophages rather than endothelial cells.
Discussion
CECs in the peripheral blood have been widely recognized as a marker of angiogenesis. Most studies have relied on multiparametric flow cytometry to identify endothelial cells because of the limited specificity of the markers used for CEC detection, which can also be expressed by other hematopoietic cells (16, 39) . CECs are currently defined as cells that express CD31 and other markers such as CD146, CD34, or CD105, but not CD45, a pan-leukocyte marker (7, 11) . However, their rareness and phenotypic overlap with other hematopoietic cells have led to controversies about the identification and determination of CECs in peripheral blood. Therefore, the present study focused on assessing the accuracy of current flow-cytometric techniques for the identification of CECs and the immunofluorescence phenotyping of CECs using different markers. Our results suggest that those cells that meet the conventional criteria to be defined as CECs are derived from a monocyte lineage rather than having an endothelial origin. Healthy subjects Cancer patients Figure 3 . Differential levels of CEC candidates in patients with gynecologic cancer (n ¼ 56) and healthy volunteers (n ¼ 44). PBMCs were analyzed by three-color flow cytometry followed by the gating strategy described in Fig. 2B Autofluorescence is an important consideration when conducting polychromatic flow-cytometric analyses. Because monocytes have higher levels of autofluorescence than lymphocytes, these 2 types of cells should be analyzed separately (29) . The frequency of CECs has mostly been analyzed by gating the lymphocyte and monocyte populations as a whole without separation, which can lead to falsenegative or false-positive results. To overcome this potential defect, we first gated FSC low /SSC low fraction (mostly lymphocytes) and then subgated CD45 À /CD31 þ cells for a more detailed and accurate characterization. In addition, we also showed that FMO is a more accurate control to set the boundaries for the analysis of rare cells such as CECs as described previously (31) .
Several studies have shown evidences that CECs, defined as DNA
þ immunophenotypes, are significantly elevated in the peripheral blood of patients with cancer than healthy subjects (41, 42) . The origin of the cells was confirmed as endothelial cells by morphology, immunohistochemistry, gene expression, and the presence of Weibel-Palade bodies. However, there have been scientific issues to be improved that the effects of various fluorescent compensation methods on the detection of CECs were not considered. Moreover, expression of several lineage markers other than endothelial cell origin should be fully investigated to identify the genuine origin of those cells, because the immunophenotypes can be overlapped among cells We could not detect the CD45
the peripheral blood of patients with gynecologic cancer; however, it remains to be further tested and compared among patients with different types or sites of malignancies. For instance, endothelial cells in hemangioma tissues showed negative immunoreactivity for CD146 (43) , whereas the expression of CD146 was highly increased in the blood vessels of breast carcinoma (44) . Because flow cytometry is not sensitive enough to obtain reproducible results when analyzing rare cells such as CECs, the results of these analyses should be interpreted with caution (45) . The frequency of CECs in the peripheral blood of the healthy population is between 1 Â 10 À7 and 1 Â 10
À5
per leukocyte (0-20 cells/mL of venous blood; refs. 20, 46 Fig. S2 ). Prokopi and colleagues showed that the endothelial phenotype may arise in mononuclear cells through the uptake of platelet microparticles (derived from the disintegration of platelets during mononuclear cell preparation) that abundantly contain marker proteins such as CD31 and vWF (50) . More importantly, monocytes in the peripheral blood are known to exhibit versatile and flexible differentiation potentials and functions, as they can differentiate into macrophages, dendritic cells, osteoclasts, microglia, or even endothelial-like cells (51) . Myeloid lineage cells including monocytes were reported to express markers that were expressed in both endothelial cells and monocytes (22, 49, (52) (53) (54) . Furthermore, circulating CD31 þ cells, which can contribute to the development of new blood vessels, were shown to be monocytes in an elaborate animal model (24) . In summary, our results showed that CD45 À /CD31 þ / CD105 þ circulating cells detected by flow cytometry under gating conditions we established, which were significantly increased in the peripheral blood of patients with gynecologic cancer, were not CECs but rather monocytes, suggesting that the conventional flow-cytometric techniques used for the identification of cell subpopulations could be improved by adjusting gating conditions. Further study is needed to identify the biologic significance of these cells and their function in relation to angiogenesis.
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